ArticleThe oncologist2025

Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies.

Yeon Hee Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.